• Citer

Trastuzumab in HER2-negative early breast cancer as adjuvant treatment for circulating tumor cells (CTCs) (Treat CTC).

par Ignatiadis, Michail ;Messina, Carlo;Litière, Saskia;Mavroudis, Dimitris;Dittrich, C;Kong, A;Janni, Wolfgang;Sotiriou, Christos ;Piccart-Gebhart, Martine ;Pierga, Jean-Yves;Rack, B
Référence San Antonio Breast Cancer Symposium 2014(37: 9-13/12/2014: San Antonio, Tx, USA), SABCS 2014 Resources
Publication Publié, 2014-12

Abstract de conférence

• Détails

Titre:	Trastuzumab in HER2-negative early breast cancer as adjuvant treatment for circulating tumor cells (CTCs) (Treat CTC).
Auteur:	Ignatiadis, Michail; Messina, Carlo; Litière, Saskia; Mavroudis, Dimitris; Dittrich, C; Kong, A; Janni, Wolfgang; Sotiriou, Christos; Piccart-Gebhart, Martine; Pierga, Jean-Yves; Rack, B
Informations sur la publication:	San Antonio Breast Cancer Symposium 2014(37: 9-13/12/2014: San Antonio, Tx, USA), SABCS 2014 Resources
Statut de publication:	Publié, 2014-12
Sujet CREF:	Cancérologie
	Médecine pathologie humaine
	Sciences bio-médicales et agricoles
Note générale:	Abstract [OT1-2-02] - Session Ongoing Clinical Trials: Ongoing Clinical Trials 1: Circulating Tumor Cells - oral presentation - 10/12/2014
Langue:	Anglais